Bibliography
- Lees AJ, Hardy J, Revesz T. Parkinson's disease. Lancet 2009;373:2055-66
- Covy JP, Giasson BI. Identification of compounds that inhibit the kinase activity of leucine-rich repeat kinase 2. Biochem Biophys Res Comm 2009;378:473-7
- Greggio E, Jain S, Kingsbury S, Kinase activity is required for the toxic effects of mutant LRRK2/dardarin. Neurobiol Dis 2006;23:329-41
- Lee BD, Shin J-H, VanKampen J, Inhibitors of leucine-rich repeat kinase-2 protect against models of Parkinson's disease. Nat Med 2010;16:998-1000
- Imai Y, Gehrke S, Wang H-Q, Phosphorylation of 4E-BP by LRRK2 affects the maintenance of dopaminergic neurons in Drosophila. EMBO J 2008;27:2432-43
- Hirsch EC, Hunot S. Neuroinflammation in Parkinson's disease: a target for neuroprotection? Lancet Neurol 2009;8:382-97
- Buolamwini JK. Cell cycle molecular targets in novel anticancer drug discovery. Curr Pharm Des 2000;6:379-92
- Anand VS, Reichling LJ, Lipinski K, Investigation of leucine-rich repeat kinase 2: enzymological properties and novel assays. FEBS J 2009;276:466-78
- Nichols RJ, Dzamko N, Hutti JE, Substrate specificity and inhibitors of LRRK2, a protein kinase mutated in Parkinson's disease. Biochem J 2009;424:47-60
- Liu M, Poulose S, Schuman E, Development of a mechanism-based high-throughput screen assay for leucine-rich repeat kinase 2 – discovery of LRRK2 inhibitors. Anal Biochem 2010;404:186-92